Tofacitinib for immune-based amyotrophic lateral sclerosis
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests whether the drug tofacitinib can help people with ALS by calming an overactive immune system. You’ll need a genetic test to see if your immune profile matches what the study is looking for.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your breathing strength must be at least 60% of normal for your age and height.
- You must have an ALS diagnosis that meets specific criteria.
- You must be willing to take a genetic test (from blood or cheek swab) to check if your immune system is overactive in a way that this drug may help.
- You must not be on permanent ventilator support.
- You must not have serious infections like HIV, active hepatitis B or C, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
This trial tests whether a new medicine, made of tiny capsules containing a protein called nerve growth factor, can help people with ALS. It aims to see if the treatment can slow the disease and improve symptoms.
This study tests an investigational drug called tazbentetol for people with ALS (amyotrophic lateral sclerosis), a disease that affects nerve cells controlling muscles. The goal is to see if it is safe and effective, and it may help slow the progression of the disease.
This trial tests whether an experimental drug called tideglusib can slow the progression of ALS. It is for people with a recent ALS diagnosis whose breathing is still fairly strong.
This trial tests whether tofacitinib, a pill that calms the immune system, can help people whose heart inflammation caused by cancer immunotherapy (called ICI) is not improving with steroid treatment. It may offer a new option for those with this rare but serious side effect.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.